Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer
Defence Therapeutics (OTCQB: DTCFF) has announced progress in its cancer therapy programs utilizing its proprietary Accum® technology in both Antibody Drug Conjugates (ADCs) and radiopharmaceuticals. The company's Accum®-based ADCs have shown enhanced efficacy in preclinical cancer models compared to conventional ADCs.
Defence is conducting studies through the Canadian Nuclear Laboratories under the CNRI-H program, focusing on biodistribution, pharmacokinetic profiles, and therapeutic potency. The company operates primarily from its Montreal laboratory while planning U.S. expansion. The target markets show significant potential, with the global ADC market projected to reach $29.9 billion by 2034 (9.23% CAGR) and the radiopharmaceutical market expected to hit $16.87 billion by 2033 (9.9% CAGR).
Defence Therapeutics (OTCQB: DTCFF) ha annunciato progressi nei suoi programmi di terapia oncologica utilizzando la sua tecnologia proprietaria Accum® sia negli Antibody Drug Conjugates (ADC) che nei radiofarmaci. Gli ADC basati su Accum® hanno dimostrato una maggiore efficacia in modelli preclinici di cancro rispetto agli ADC convenzionali.
Defence sta conducendo studi presso i Canadian Nuclear Laboratories nell'ambito del programma CNRI-H, concentrandosi sulla biodistribuzione, i profili farmacocinetici e la potenza terapeutica. L'azienda opera principalmente dal suo laboratorio di Montreal, con piani di espansione negli Stati Uniti. I mercati target mostrano un potenziale significativo, con il mercato globale degli ADC previsto raggiungere i 29,9 miliardi di dollari entro il 2034 (CAGR 9,23%) e il mercato dei radiofarmaci stimato a 16,87 miliardi di dollari entro il 2033 (CAGR 9,9%).
Defence Therapeutics (OTCQB: DTCFF) ha anunciado avances en sus programas de terapia contra el cáncer que utilizan su tecnología patentada Accum® tanto en Conjugados Anticuerpo-Fármaco (ADC) como en radiofármacos. Los ADC basados en Accum® han demostrado una eficacia mejorada en modelos preclínicos de cáncer en comparación con los ADC convencionales.
Defence está realizando estudios a través de los Canadian Nuclear Laboratories bajo el programa CNRI-H, enfocándose en la biodistribución, perfiles farmacocinéticos y potencia terapéutica. La compañía opera principalmente desde su laboratorio en Montreal, mientras planea expandirse en EE.UU. Los mercados objetivo muestran un potencial significativo, con el mercado global de ADC proyectado para alcanzar los 29.9 mil millones de dólares para 2034 (CAGR 9.23%) y el mercado de radiofármacos esperado en 16.87 mil millones de dólares para 2033 (CAGR 9.9%).
Defence Therapeutics (OTCQB: DTCFF)는 독자적인 Accum® 기술을 활용한 항체-약물 접합체(ADC)와 방사성 의약품 분야에서 암 치료 프로그램의 진전을 발표했습니다. 회사의 Accum® 기반 ADC는 기존 ADC에 비해 전임상 암 모델에서 향상된 효능을 보였습니다.
Defence는 CNRI-H 프로그램 하에 캐나다 원자력 연구소(Canadian Nuclear Laboratories)에서 생체 분포, 약동학 프로필 및 치료 효능에 중점을 둔 연구를 진행하고 있습니다. 회사는 주로 몬트리올 연구소에서 운영되며 미국 진출을 계획 중입니다. 목표 시장은 상당한 잠재력을 보이며, 글로벌 ADC 시장은 2034년까지 299억 달러에 이를 것으로 예상되며(연평균 성장률 9.23%), 방사성 의약품 시장은 2033년까지 168억 7천만 달러에 달할 것으로 전망됩니다(연평균 성장률 9.9%).
Defence Therapeutics (OTCQB : DTCFF) a annoncé des avancées dans ses programmes de thérapie contre le cancer utilisant sa technologie propriétaire Accum® dans les conjugués anticorps-médicaments (ADC) et les radiopharmaceutiques. Les ADCs basés sur Accum® ont montré une efficacité améliorée dans des modèles précliniques de cancer comparés aux ADC conventionnels.
Defence mène des études via les Laboratoires Nucléaires Canadiens dans le cadre du programme CNRI-H, se concentrant sur la biodistribution, les profils pharmacocinétiques et la puissance thérapeutique. La société opère principalement depuis son laboratoire de Montréal tout en prévoyant une expansion aux États-Unis. Les marchés cibles présentent un potentiel important, avec le marché mondial des ADC prévu atteindre 29,9 milliards de dollars d'ici 2034 (TCAC de 9,23 %) et le marché des radiopharmaceutiques estimé à 16,87 milliards de dollars d'ici 2033 (TCAC de 9,9 %).
Defence Therapeutics (OTCQB: DTCFF) hat Fortschritte in seinen Krebstherapieprogrammen mit der firmeneigenen Accum®-Technologie sowohl bei Antikörper-Wirkstoff-Konjugaten (ADCs) als auch bei Radiopharmazeutika bekannt gegeben. Die Accum®-basierten ADCs zeigten in präklinischen Krebsmodellen eine verbesserte Wirksamkeit im Vergleich zu herkömmlichen ADCs.
Defence führt Studien im Rahmen des CNRI-H-Programms bei den Canadian Nuclear Laboratories durch, die sich auf Biodistribution, pharmakokinetische Profile und therapeutische Potenz konzentrieren. Das Unternehmen operiert hauptsächlich von seinem Labor in Montreal aus und plant eine Expansion in die USA. Die Zielmärkte zeigen erhebliches Potenzial, wobei der globale ADC-Markt bis 2034 voraussichtlich 29,9 Milliarden US-Dollar erreichen wird (CAGR 9,23 %) und der Radiopharmazeutika-Markt bis 2033 auf 16,87 Milliarden US-Dollar anwachsen soll (CAGR 9,9 %).
- Preclinical studies show enhanced efficacy of Accum®-based ADCs compared to conventional ADCs
- Ongoing collaborations with ADC companies for potential licensing deals
- Received CNRI-H program grant for radiopharmaceutical studies
- Operating in rapidly growing markets with strong CAGR projections
- Studies and optimizations still ongoing with no completed results yet
- No confirmed partnerships or licensing deals at present
Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that its highly impactful programs on ADC and Radiopharma programs, which includes collaborations and preclinical studies on cancer therapies with Accum® are ongoing.
Defence's Accum®-based ADCs have demonstrated enhanced intracellular delivery and cytotoxic activity in multiple preclinical cancer models compared to conventional ADCs. Defence continues to advance studies that validate additional Accum®-based ADCs, including optimization to increase the value and to attract Pharmaceuticals and Biotech companies for potential licensing deals and co-development opportunities. In addition, collaborations and preclinical studies with ADCs companies are ongoing to validate and confirm the significant efficacy improvement when Defence's Accum® technology is added to their respective ADC.
Defence's Radiopharma focused program continues to enhance the optimization of Accum® radiolabelling with studies performed by the Canadian Nuclear Laboratories ("CNL") under notably the CNRI-H program that Defence was granted. The complete study is being performed, including biodistribution, pharmacokinetic profile and therapeutic potency, using radiolabelled Accum® with selected antibodies. Defence's scientific team is confident that the addition of the Accum® technology being applied in the radiopharmaceuticals industry may be transformative.
The global antibody drug conjugate (ADC) market size is projected to grow from USD 13.51 billion in 2025 to USD 29.9 billion by 2034, at a compound annual growth rate (CAGR) of
https://www.towardshealthcare.com/insights/antibody-drug-conjugate-market-sizing
https://straitsresearch.com/report/radiopharmaceutical-market
Defence's Accum® technology optimization is also currently ongoing, with more detail to be released upon completion of all the studies related.
The Company will announce key results when they become available and completed as well as details on partnerships when and if deals and licensing occurred. Defence continues to work on studies in Canada, mainly at Defence's laboratory located in Montreal, Canada and in parallel the Company continues pursuing its plan to expand its presence to the US.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.
For further information:
Sebastien Plouffe, Founder, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258655
FAQ
What is the market potential for Defence Therapeutics (DTCFF) ADC technology?
How does Defence Therapeutics' Accum® technology improve cancer treatments?
What partnerships does Defence Therapeutics have for its Accum® technology?
What is the projected growth of the radiopharmaceutical market that Defence Therapeutics is targeting?
Where is Defence Therapeutics conducting its research studies?
